RxDoctor Payments Data

George Miranda, MD

Hematology & Oncology · Mission Viejo, CANPI 1558545038

Payments from drug & device makers

$18,034in general payments, 2019–2025

Across 809 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • Novartis$2K
  • AstraZeneca$2K
  • Johnson & Johnson$979
  • Incyte Corporation$778
  • E.r. Squibb & Sons, L.L.C.$577
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$17,83799%
  • Education$1971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck68$1,669
Novartis78$1,636
AstraZeneca(2 entities)70$1,516
Johnson & Johnson(2 entities)41$979
Incyte Corporation34$778
E.r. Squibb & Sons, L.L.C.41$577
Pfizer22$510
Pharmacyclics LLC, An Abbvie Company20$472
AbbVie19$463
Daiichi Sankyo Inc.17$426
Takeda Pharmaceuticals U.S.A., Inc.16$417
Lilly USA, LLC19$406
Bristol Myers Squibb24$390
Genentech USA, Inc.19$389
Astellas Pharma US Inc17$387
GSK16$343
Eisai Inc.15$324
Bayer14$313
Karyopharm Therapeutics Inc.11$299
Regeneron Healthcare Solutions, Inc.9$285
Seagen Inc.14$283
Exelixis Inc.9$267
Amgen11$258
Gilead(2 entities)11$246
Beigene USA, Inc.9$244
Pharmaessentia USA Corporation7$220
Blueprint Medicines Corporation9$215
Rigel Pharmaceuticals, Inc.11$201
AVEO Pharmaceuticals, Inc.8$195
Sanofi8$187
EMD Serono, Inc.9$182
Deciphera Pharmaceuticals Inc.6$164
Puma Biotechnology, Inc.6$158
Ipsen Biopharmaceuticals, Inc7$125
Array Biopharma Inc7$117
Sumitomo Pharma America, Inc.5$113
Tersera Therapeutics LLC4$113
Taiho Oncology, Inc.5$109
Stemline Therapeutics Inc.4$101
Tempus AI, Inc3$88
Genmab U.S., Inc.3$83
Beone Medicines USA, Inc.3$83
Boehringer Ingelheim3$81
Sobi, Inc4$79
ADC Therapeutics America, Inc.3$77
Coherus Oncology, Inc.3$69
Myovant Sciences Inc.3$69
EUSA Pharma (US) LLC4$67
Mirati Therapeutics, Inc.3$65
Servier Pharmaceuticals LLC3$63
Jazz Pharmaceuticals Inc.3$59
Alnylam Pharmaceuticals Inc.2$49
Mylan Institutional Inc.2$48
Recordati_rare_diseases_inc.2$48
Iovance Biotherapeutics, Inc.2$47
Octapharma USA, Inc.1$47
Springworks Therapeutics, Inc.2$46
Agios Pharmaceuticals, Inc.2$44
CTI Biopharma Corp.2$43
Teva Pharmaceuticals USA, Inc.2$42

How this compares

$18,034 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$321,653
Medicare patients
519
Services billed
9,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide72$1,234,840
XtandiEnzalutamide39$498,988
Lenalidomide40$483,040
JakafiRuxolitinib Phosphate26$450,295
RetevmoSelpercatinib20$420,632
TagrissoOsimertinib Mesylate22$366,697
ImbruvicaIbrutinib48$320,669
PomalystPomalidomide14$312,646
CalquenceAcalabrutinib Maleate31$277,294
IbrancePalbociclib13$196,970
BrukinsaZanubrutinib12$170,306
VenclextaVenetoclax12$139,970
LumakrasSotorasib12$127,506
VotrientPazopanib Hcl11$117,600
Abiraterone Acetate33$76,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$390$1,234,84072 claims
AstraZenecaTagrisso, Calquence$1,516$643,99153 claims
Astellas Pharma US IncXtandi$387$498,98839 claims
Incyte CorporationJakafi$778$450,29526 claims
Lilly USA, LLCRetevmo$406$420,63220 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$472$320,66948 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$577$312,64614 claims
PfizerIbrance, Eliquis$510$213,19129 claims
Beigene USA, Inc.Brukinsa$244$170,30612 claims
AbbVieVenclexta$463$139,97012 claims
Johnson & JohnsonXarelto, Procrit$979$139,85496 claims
AmgenLumakras$258$127,50612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →